세계의 특발성 폐섬유증 시장 보고서(2025년)

Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by the gradual and continuous deterioration of the tissue surrounding the air sacs, known as alveoli, in the lungs. This condition results in the accumulation of scar tissue (fibrosis) within the lungs, hindering the efficient transfer of oxygen into the bloodstream.

The main types of drugs used in the treatment of idiopathic pulmonary fibrosis include nintedanib, pirfenidone, and others. Nintedanib is a medication prescribed for the treatment of specific lung conditions, including idiopathic pulmonary fibrosis (IPF), which is an interstitial lung disease with a progressive phenotype, and interstitial lung disease associated with systemic sclerosis. These drugs operate through various modes of action, such as antifibrotic agents and tyrosine kinase inhibitors, and can be administered through various routes, including oral and parenteral. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online platforms, serving various end users such as hospitals, clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The idiopathic pulmonary fibrosis market research report is one of a series of new reports from The Business Research Company that provides idiopathic pulmonary fibrosis market statistics, including idiopathic pulmonary fibrosis industry global market size, regional shares, competitors with idiopathic pulmonary fibrosis market share, detailed idiopathic pulmonary fibrosis market segments, market trends, and opportunities, and any further data you may need to thrive in the idiopathic pulmonary fibrosis industry. This idiopathic pulmonary fibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $4.15 billion in 2024 to $4.37 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to increasing aging population, limited treatment options, rising disease awareness, healthcare infrastructure development.

The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $5.72 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to expanded research and development, precision medicine approach, increasing disease incidence, advancements in biomarker development, government initiatives and funding. Major trends in the forecast period include advancements in diagnostic techniques, emergence of targeted therapies, telemedicine and remote monitoring, combination therapies, advancements in lung transplantation.

The forecast of 6.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to antifibrotic drugs and high-flow oxygen systems imported from Japan and Canada, potentially worsening patient outcomes and increasing pulmonology care burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The idiopathic pulmonary fibrosis market is poised for growth, primarily driven by the increasing prevalence of fibrotic diseases. These conditions, marked by the abnormal accumulation of fibrous connective tissue in various organs, receive treatment through idiopathic pulmonary fibrosis (IPF) drugs targeting fibrosis-related signaling pathways. Notably, the American Lung Association reported in December 2022 that around 207,000 individuals in the United States were affected, with approximately 58,000 new IPF cases diagnosed annually. This condition, more prevalent in men and predominantly affecting those aged over 50, underscores the significant role of escalating fibrotic diseases in driving the idiopathic pulmonary fibrosis market.

The growing geriatric population is anticipated to drive the expansion of the idiopathic pulmonary fibrosis (IPF) market in the future. The geriatric population consists of elderly individuals within a specific society or community. Aging is linked to both structural and functional changes in the lungs, which increase the vulnerability of older adults to respiratory diseases like IPF. This age-related susceptibility contributes to the rising demand for IPF treatments. For example, in October 2022, the World Health Organization, a specialized health agency based in the US, reported that by 2030, 1 in 6 people globally will be aged 60 or older, with the number of individuals in this age group expected to reach 2.1 billion by 2050. Consequently, the increasing geriatric population is propelling the growth of the idiopathic pulmonary fibrosis market.

A notable trend gaining momentum in the idiopathic pulmonary fibrosis market is product innovation. Major companies in the industry are placing emphasis on developing innovative products to strengthen their market positions and gain a competitive advantage. For instance, in May 2022, Sandoz, a Swiss-based pharmaceutical company, introduced a generic version of pirfenidone, the first AB-rated equivalent to Genentech's Esbriet, for treating idiopathic pulmonary fibrosis. This generic medication, accessible through specialty pharmacies, offers eligible patients the benefit of a USD 0 co-pay program.

Companies in the idiopathic pulmonary fibrosis market are directing their efforts toward innovative products such as anti-fibrotic small-molecule inhibitors to sustain their market positions. These inhibitors, designed to target and inhibit fibrotic processes in the body, represent a significant advancement. In June 2023, Insilico Medicine, a US-based biotechnology company, initiated Phase II clinical trials for INS018_055, the world's first anti-fibrotic small molecule inhibitor designed through generative artificial intelligence. This groundbreaking approach utilizing AI in drug discovery showcases the potential for progress in idiopathic pulmonary fibrosis treatment.

In October 2022, AbbVie Inc., a US-based pharmaceutical company, acquired DJS Antibodies Ltd., a UK-based biotechnology company specializing in the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. This acquisition aims to enhance AbbVie's antibody research capabilities and expand its immunology portfolio.

Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the idiopathic pulmonary fibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The idiopathic pulmonary fibrosis (IPF) market consists of sales of anti-inflammatory, MAPK inhibitors, autotoxin inhibitors and corticosteroids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Idiopathic Pulmonary Fibrosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on idiopathic pulmonary fibrosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for idiopathic pulmonary fibrosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The idiopathic pulmonary fibrosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Nintedanib; Pirfenidone; Other Drug Types
• 2) By Mode Of Action: Antifibrotic Agents; Tyrosine Kinase Inhibitors; Other Modes Of Action
• 3) By Route Of Administration: Oral; Parenteral
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Providers
• 5) By End Users: Hospitals And Clinics; Other End Users
• Subsegments:
• 1) By Nintedanib: Indications; Dosage Forms; Administration Routes
• 2) By Pirfenidone: Indications; Dosage Forms; Administration Routes
• 3) By Other Drug Types: Specific Agents Or Classes; Emerging Therapies; Combination Therapies
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca PLC; Sanofi S.A.; Gilead Sciences Inc.; Toray Industries Inc.; Boehringer Ingelheim International GmbH; Viatris Inc.; Sun Pharmaceutical Industries Limited; Shionogi and Co. Ltd.; Cipla Inc.; Zydus Lifesciences Ltd.; Chong Kun Dang Pharmaceutical Corp.; Kyorin Pharmaceutical Co. Ltd.; Galapagos NV; Veracyte Inc.; Genentech Inc.; FibroGen Inc.; GNI Group Ltd.; Pliant Therapeutics Inc.; Pulmatrix Inc.; Galimedix Therapeutics Inc.; Avalyn Pharma Inc.; MediciNova Inc.; Liminal BioSciences Inc.; Beijing Continent Pharmaceuticals Company; Galecto Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Idiopathic Pulmonary Fibrosis Market Characteristics

3. Idiopathic Pulmonary Fibrosis Market Trends And Strategies

4. Idiopathic Pulmonary Fibrosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Idiopathic Pulmonary Fibrosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Idiopathic Pulmonary Fibrosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Idiopathic Pulmonary Fibrosis Market Growth Rate Analysis
• 5.4. Global Idiopathic Pulmonary Fibrosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Idiopathic Pulmonary Fibrosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Idiopathic Pulmonary Fibrosis Total Addressable Market (TAM)

6. Idiopathic Pulmonary Fibrosis Market Segmentation

• 6.1. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nintedanib
• Pirfenidone
• Other Drug Types
• 6.2. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antifibrotic Agents
• Tyrosine Kinase Inhibitors
• Other Modes Of Action
• 6.3. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Providers
• 6.5. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Other End Users
• 6.6. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Nintedanib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Indications
• Dosage Forms
• Administration Routes
• 6.7. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Pirfenidone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Indications
• Dosage Forms
• Administration Routes
• 6.8. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Specific Agents Or Classes
• Emerging Therapies
• Combination Therapies

7. Idiopathic Pulmonary Fibrosis Market Regional And Country Analysis

• 7.1. Global Idiopathic Pulmonary Fibrosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Idiopathic Pulmonary Fibrosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Idiopathic Pulmonary Fibrosis Market

• 8.1. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Idiopathic Pulmonary Fibrosis Market

• 9.1. China Idiopathic Pulmonary Fibrosis Market Overview
• 9.2. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Idiopathic Pulmonary Fibrosis Market

• 10.1. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Idiopathic Pulmonary Fibrosis Market

• 11.1. Japan Idiopathic Pulmonary Fibrosis Market Overview
• 11.2. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Idiopathic Pulmonary Fibrosis Market

• 12.1. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Idiopathic Pulmonary Fibrosis Market

• 13.1. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Idiopathic Pulmonary Fibrosis Market

• 14.1. South Korea Idiopathic Pulmonary Fibrosis Market Overview
• 14.2. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Idiopathic Pulmonary Fibrosis Market

• 15.1. Western Europe Idiopathic Pulmonary Fibrosis Market Overview
• 15.2. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Idiopathic Pulmonary Fibrosis Market

• 16.1. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Idiopathic Pulmonary Fibrosis Market

• 17.1. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Idiopathic Pulmonary Fibrosis Market

• 18.1. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Idiopathic Pulmonary Fibrosis Market

• 19.1. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Idiopathic Pulmonary Fibrosis Market

• 20.1. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Idiopathic Pulmonary Fibrosis Market

• 21.1. Eastern Europe Idiopathic Pulmonary Fibrosis Market Overview
• 21.2. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Idiopathic Pulmonary Fibrosis Market

• 22.1. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Idiopathic Pulmonary Fibrosis Market

• 23.1. North America Idiopathic Pulmonary Fibrosis Market Overview
• 23.2. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Idiopathic Pulmonary Fibrosis Market

• 24.1. USA Idiopathic Pulmonary Fibrosis Market Overview
• 24.2. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Idiopathic Pulmonary Fibrosis Market

• 25.1. Canada Idiopathic Pulmonary Fibrosis Market Overview
• 25.2. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Idiopathic Pulmonary Fibrosis Market

• 26.1. South America Idiopathic Pulmonary Fibrosis Market Overview
• 26.2. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Idiopathic Pulmonary Fibrosis Market

• 27.1. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Idiopathic Pulmonary Fibrosis Market

• 28.1. Middle East Idiopathic Pulmonary Fibrosis Market Overview
• 28.2. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Idiopathic Pulmonary Fibrosis Market

• 29.1. Africa Idiopathic Pulmonary Fibrosis Market Overview
• 29.2. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Idiopathic Pulmonary Fibrosis Market Competitive Landscape And Company Profiles

• 30.1. Idiopathic Pulmonary Fibrosis Market Competitive Landscape
• 30.2. Idiopathic Pulmonary Fibrosis Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Idiopathic Pulmonary Fibrosis Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Gilead Sciences Inc.
• 31.3. Toray Industries Inc.
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Viatris Inc.
• 31.6. Sun Pharmaceutical Industries Limited
• 31.7. Shionogi and Co. Ltd.
• 31.8. Cipla Inc.
• 31.9. Zydus Lifesciences Ltd.
• 31.10. Chong Kun Dang Pharmaceutical Corp.
• 31.11. Kyorin Pharmaceutical Co. Ltd.
• 31.12. Galapagos NV
• 31.13. Veracyte Inc.
• 31.14. Genentech Inc.
• 31.15. FibroGen Inc.

32. Global Idiopathic Pulmonary Fibrosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Idiopathic Pulmonary Fibrosis Market

34. Recent Developments In The Idiopathic Pulmonary Fibrosis Market

35. Idiopathic Pulmonary Fibrosis Market High Potential Countries, Segments and Strategies

• 35.1 Idiopathic Pulmonary Fibrosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Idiopathic Pulmonary Fibrosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Idiopathic Pulmonary Fibrosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer